ORYZON Unveils Groundbreaking Findings from PORTICO: A Global Phase IIb Vafidemstat Trial for Borderline Personality Disorder (BPD) at the European College of Neuropsychopharmacology (ECNP) Conference
Madrid and Cambridge, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE)
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, has announced that it will be presenting final data from its Phase IIb PORTICO trial of vafidemstat in patients with Borderline Personality Disorder (BPD) at the New Medications Symposium. This special symposium is focused on clinical trials of new compounds within the 37th European College of Neuropsychopharmacology (ECNP-2024) congress, currently being held in Milan, Italy.
Oryzon’s Oral Presentation
Oryzon’s oral presentation, titled “Final results: Phase 2b PORTICO Study: Efficacy of Vafidemstat in Borderline Personality Disorder,” will be delivered by Dr. Michael Ropacki, Oryzon’s Chief Medical Officer for CNS. Additionally, the results will also be presented as a poster at ECNP-2024.
When groundbreaking research is unveiled at prestigious conferences such as the ECNP, it signifies a significant step forward in the field of neuropsychopharmacology. The validation of vafidemstat’s efficacy in treating BPD could potentially revolutionize the treatment landscape for a disorder that has long been plagued by stigma, misunderstanding, and limited therapeutic options. BPD is a complex and challenging mental health condition characterized by unstable moods, relationships, and self-image, as well as impulsive behavior and intense emotional reactions.
The PORTICO trial’s results hold the promise of providing hope to individuals living with BPD, as well as their loved ones and caregivers. Effective pharmacological interventions can help alleviate symptoms, improve quality of life, and promote recovery for those grappling with this debilitating disorder.
As we eagerly await the detailed findings from the Phase IIb trial, it is crucial to acknowledge the dedication and expertise of the researchers, clinicians, and study participants who have contributed to this important work. Their commitment to advancing the understanding and treatment of BPD is commendable and serves as a beacon of light for those affected by mental health challenges.
How this will affect me:
As an individual who may be living with Borderline Personality Disorder or knows someone who is, the unveiling of groundbreaking findings from the PORTICO trial could potentially impact your journey towards healing and recovery. The introduction of vafidemstat as a potential treatment option may offer new hope and possibilities for managing the symptoms of BPD, ultimately enhancing your quality of life and well-being.
How this will affect the world:
The global presentation of the final data from the Phase IIb PORTICO trial at a renowned conference like ECNP has the potential to have a profound impact on the world. By shedding light on effective pharmacological interventions for Borderline Personality Disorder, this research has the power to challenge stigma, improve access to care, and foster greater understanding and compassion towards individuals grappling with mental health challenges.
Conclusion:
ORYZON’s unveiling of the groundbreaking findings from the PORTICO trial at the ECNP conference marks a significant milestone in the field of neuropsychopharmacology. The potential efficacy of vafidemstat in treating Borderline Personality Disorder offers hope for individuals living with this complex condition and has the power to shape the future of mental health treatment. As we anticipate further insights and advancements in this area, let us embrace the transformative impact that innovative research and compassionate care can have on individuals, communities, and societies worldwide.
